Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 28:13:1190269.
doi: 10.3389/fonc.2023.1190269. eCollection 2023.

Editorial: Advances in the understanding and treatment of cutaneous lymphoma

Andrea Bernardelli  1 , Lorenzo Falchi  2 , Jianjun Qiao  3 , Carlo Visco  1
Affiliations
Editorial

Editorial: Advances in the understanding and treatment of cutaneous lymphoma

Andrea Bernardelli et al. Front Oncol. .
No abstract available

Keywords: JAK/STAT; PCL; cutaneous B-cell lymphomas; cutaneous T-cell lymphomas; mogamulizumab; non Hodgkin’s lymphoma; primary cutaneous lymphoma; skin cancer.

PubMed Disclaimer

Conflict of interest statement

LF research funding: Genmab, Abbvie, Roche, Genentech. Consultancy: Genmab, Abbvie, Roche, Genentech. Advisory board: Genmab, Abbvie, Genentech, Seagen, Astrazeneca, ADC therapeutics. Travel reimbursements: Genmab. CV research funding: Abbvie, Janssen. Consultancy: Janssen, Pfizer. Speaker bureau: Abbvie, Janssen, Gentili, Pfizer, Incyte, Servier, AstraZeneca, Kyowa Kirin. Advisory board: Abbvie, Kite-Gilead, Janssen, Gentili, Novartis, Pfizer, Roche, Incyte, BMS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Advances in the understanding and treatment of cutaneous lymphoma

References

    1. Olsen EA, Whittaker S, Willemze R, Brown LP, Foss F, Geskin L, et al. . Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood (2022) 140(5):419–37. doi: 10.1182/blood.2021012057 - DOI - PMC - PubMed

Publication types

LinkOut - more resources